“Just as much of medicine has begun to undergo a digital transformation in the past decade, so has pathology. Now, biomarkers, which are indications of particular features of cancer and are essential to diagnosis and treatment, are beginning their own digital revolution.” Dr. Joe Oakley, Medical Director of Biomarker Development at Paige, shared with Labiotech how digital biomarker assays are poised to transform the future of cancer diagnosis, and provides a look at how Paige has been pioneering the path forward through our first digital biomarker assay, HER2Complete.
Read the full article on Labiotech.edu
—
Oakley, G. (2023b, February 2). How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic. Https://Www.Labiotech.Eu/. https://www.labiotech.eu/opinion/digital-biomarker-assays-deep-learning-clinical-trials-clinic/?utm_content=237613151&utm_medium=social&utm_source=linkedin&hss_channel=lcp-11504814
